The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial

Reinoud E. Knops et al.

Summary: In this trial, there was no difference in shock efficacy between S-ICD and TV-ICD. Although patients in the S-ICD group were more likely to receive shocks, the total number of appropriate shocks did not differ between the two groups.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study

Pier D. Lambiase et al.

Summary: This study reports the 5-year outcomes of EFFORTLESS registry patients with early generation subcutaneous implantable cardioverter-defibrillator (S-ICD) devices. The study found that the spontaneous shock efficacy remained consistently high over the 5-year period and very few patients required replacement with a transvenous device. Additionally, early arrhythmic episodes did not predict later complications.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Implantable Cardioverter Defibrillators and Chronic Kidney Disease

James N. Kiage et al.

Summary: Patients with chronic kidney disease (CKD) or end stage renal disease (ESRD) who receive treatment with ICDs are more likely to experience anti tachycardia pacing or shocks, and have higher rates of cardiac and/or all-cause mortality compared to those without CKD/ESRD. These findings suggest that routine use of ICDs in this patient population may lead to more adverse outcomes rather than benefits, with outcomes worsening as kidney function decreases.

CURRENT PROBLEMS IN CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical impact of defibrillation testing in a real-world S-ICD population: Data from the ELISIR registry

Danilo Ricciardi et al.

Summary: Implanting an S-ICD without DT does not appear to impact the safety of defibrillation therapy and overall patients' survival, with a very low rate of ineffective shocks observed.

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Intraprocedural PRAETORIAN score for early assessment of S-ICD implantation: A proof-of-concept study

Alessio Gasperetti et al.

Summary: The study confirmed the feasibility of using IP-PS during S-ICD implantation, showing a very high agreement with PP-PS obtained from two-views chest X-ray. Compared to the historical cohort, procedural time did not significantly increase in the IP-PS group, with a minimal increase in fluoroscopy time.

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis

Roberto Rordorf et al.

Summary: Comparison between S-ICD and TV-ICD in terms of clinically relevant device-related complications and inappropriate shocks found that the two are overall comparable. Patients with S-ICD had lower risk of lead complications and major procedural complications compared to those with TV-ICD, but higher risk of pocket complications.

HEART RHYTHM (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients

Mikhael F. El-Chami et al.

Summary: The infection rate in de novo transvenous (TV) ICD implants in a Medicare population was 1.9%, with significant predictors of infection including age <70 years, renal disease with dialysis, and complicated diabetes mellitus.

HEART RHYTHM (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)

Michael Glikson et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study

Giovanni B. Forleo et al.

Summary: This study compared the long-term clinical outcomes of S-ICD patients undergoing and not undergoing defibrillation testing, finding no significant differences in cardiovascular mortality and ineffective shocks between the two groups. The PRAETORIAN score was able to correctly identify patients at risk for ineffective shock conversion.

HEART RHYTHM (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience

Alessio Gasperetti et al.

Summary: The study aimed to evaluate device-related complications in a large real-world multicenter S-ICD cohort. Over 23.2 months of follow-up, the overall complication rate was 9.3%. Early unanticipated device battery depletions occurred in 2.2% of patients, while lead fracture was observed in 0.3%.

HEART RHYTHM (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems